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Abstract 
Human epidermal growth factor receptor 2 (HER2) is overexpressed/amplified in one third of breast 
cancers (BCs), and is associated with the poorer prognosis and the higher metastatic potential in BC. 
Emerging evidences highlight the role of microRNAs (miRNAs) in the regulation of several cellular 
processes, including BC.  
Methods: Here we identified, by in silico approach, a group of three miRNAs with central biological role 
(high degree centrality) in HER2+ BC. We validated their dysregulation in HER2+ BC and we analysed 
their functional role by in vitro approaches on selected cell lines and by in vivo experiments in an animal 
model.  
Results: We found that their expression is dysregulated in both HER2+ BC cell lines and human samples. 
Focusing our study on the only upregulated miRNA, miR-429, we discovered that it acts as an oncogene 
and its upregulation is required for HER2+ cell proliferation. It controls the metastatic potential of 
HER2+ BC subtype by regulating migration and invasion of the cell.  
Conclusions: In HER2+ BC oncogenic miR-429 is able to regulate HIF1α pathway by directly targeting 
VHL mRNA, a molecule important for the degradation of HIF1α. The overexpression of miR-429, 
observed in HER2+ BC, causes increased proliferation and migration of the BC cells. More important, 
silencing miR-429 succeeds in delaying tumor growth, thus miR-429 could be proposed as a therapeutic 
probe in HER2+ BC tumors. 
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Introduction 
The St.Gallen International Breast Cancer 
Conference classifies breast cancer (BC) into five 
intrinsic molecular subtypes: luminal A, luminal B, 
HER2-enriched, basal-like, and normal-like [1]. BC 
patients with overexpression of Human epidermal 
growth factor receptor 2 (HER2) have shown a poorer 
and shorter overall survival (OS) [2, 3] being HER2 
expression a predictor of metastatic BC [4]. Indeed, 
patients with HER2+ BC frequently develop 
metastases in the brain, liver and lung [5]. 
HER2 was discovered as a human 
proto-oncogene in 1985 through its homology with 
v-erbB and with the human epidermal growth factor 
receptor (EGFR) gene. HER2 gene encodes for a 
tyrosine kinase receptor, whose amplification and 
activation lead to uncontrolled cell proliferation. In 
1987, D. Slamon described amplification of HER2 
gene in ~30% of all clinical samples of BC [6]. As a 
 
Ivyspring  
International Publisher 
Theranostics 2020, Vol. 10, Issue 1 
 
 
http://www.thno.org 
51 
result, HER2 receptor is overexpressed in HER2+ BC 
patients up to 20 times more than in normal tissues 
[6]. This overexpression is involved in the cell 
proliferation maintenance, avoiding apoptosis and in 
favoring cell spreading and metastasis formation [7]. 
The actual methods for HER2+ BC diagnosis are 
based on the analysis of tissue samples by 
immunohistochemistry (IHC) of HER2 protein or in 
situ hybridization of HER2 specific transcript. This 
method is widely used as it is cost-effective, easy to be 
used for rapid evaluation in primary diagnostics and 
for rapid screens [8]. Although the optimization 
guides help the pathologists in the diagnosis [9, 10], 
the IHC approach is limited by technical features, 
such as the correct identification of the tumor areas 
within a complex tissue section, or the interpretation 
of the visual expression pattern and intensities in the 
tumor cells and in surrounding tissue [11]. Poor 
reproducibility among different laboratories, or 
among observers and pathologists in the same 
laboratory has emerged (i.e. [12]). Moreover, some 
studies highlight the existence of discordance in 25% 
of HER2+ BC cases between two different 
pathologists [13-15]. These observations pushed the 
research towards the discovery of new reliable 
diagnostic biomarkers to be used in precision 
medicine for HER2+ diagnosis.  
The main methods to define new robust 
biomarker are based on the analysis of 
high-throughput database, in order to identify 
differentially expressed genes, and on the integration 
of this information with functional pathways and 
with the biological relationships among cellular 
components (network) [16-19]. These integrative 
approaches consider also epigenetic features of the 
tumors, with a particular attention to microRNA 
(miRNA) molecules. miRNAs are small non coding 
RNA with a main role in BC development, being able 
to regulate several mRNA targets. A small change in 
miRNA expression levels could have a high impact on 
the phenotype of the cell [20]. 
In our laboratory we developed a new in silico 
integrative approach to put all the information on 
differentially expressed genes, network and 
functional pathways in relation with miRNA 
molecules, in order to identify a specific group of 
miRNAs with a main role in the development of 
HER2+ BC. In particular, we identified three miRNAs, 
namely Hsa-miR-190, Hsa-miR-429 and Hsa-miR-584 
(indicated from here on as miR-190, miR-429 and 
miR-584, respectively), having a higher degree 
centrality in HER2+ BC, being able to control the 
highest number of genes in coupled functional 
pathways. 
In this paper, we described the bioinformatics 
approach and validated the ability of these three 
miRNAs to perform differential diagnosis of HER2+ 
BC. Moreover, we focused on miR-429, the only 
upregulated miRNA of the three with a highest 
number of connections with the functional pathways, 
and we analyzed its role in controlling specific 
function altered in HER2+ BC. miR-429 demonstrated 
to be a diagnostic molecule involved in the control of 
HIF1α pathway, having as a direct target VHL gene. 
Indeed, in vitro experiments revealed that miR-429 is 
involved in the regulation of proliferation and 
metastatic potential of highly aggressive BC. In 
addition to its diagnostic properties, in vivo studies 
with xenografted mouse, showed that the treatment 
with a silencer oligonucleotide of miR-429 is able to 
cause a delay of tumor proliferation, thus making 
miR-429 a possible candidate molecule for the 
development of new therapeutic tools in HER2+ BC.  
Material and Methods 
Datasets for computational analysis 
We applied the computational approach on 
HER2+ BC dataset of IlluminaHiSeq RNASeqV2 
derived from The Cancer Genome Atlas (TCGA). We 
selected 43 HER2+ BC samples and 113 normal 
samples (NS). The expression levels of 1046 miRNAs 
and 15243 genes (excluding genes with a small 
variance) were considered. We used BC matched 
samples of mRNA and miRNA.  
Computational approach 
The computational analysis consists of 4 steps. In 
the first step we applied a differential expression 
analysis identifying pathways enriched with 
differentially expressed genes between HER2+ BC 
samples and NS. In the second step we calculated a 
measure of pathway cross-talk among pairwise 
pathways. In the third step we selected pairwise 
pathways with a machine learning approach to 
distinguish HER2+ BC samples vs NS with the best 
performance, generating a pathway cross-talk 
network. In the fourth step we applied a mutual 
information analysis in order to identify differentially 
expressed miRNAs regulating pathway cross-talk.  
The computational approach was based on a 
Monte Carlo Cross-Validation, dividing the original 
dataset into training (60%) and testing (40%) dataset. 
The first three steps were repeated 50 times on 
different generated training data set. The fourth step 
was applied on the whole dataset. To avoid problems 
of unbalanced classes, we generated randomly an 
equal number of samples for each class (HER2+ BC 
and NS). Figure 1 shows the workflow of the 
proposed computational approach. 
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Figure 1. Workflow of the proposed computational approach. 
 
Pathway enrichment analysis 
Differentially expressed genes between HER2+ 
BC and NS were identified by a statistical analysis 
using TCGAbiolinks package [21] (|logFC| >1 and 
p-value<0.01). The p-values were adjusted by the 
Benjamin-Hochberg method for multiple testing 
correction [22].  
Considering 589 pathways from the Ingenuity 
Pathway Analysis (IPA) database, we carried out a 
pathway enrichment analysis. The enrichment was 
performed using the Fisher's Exact Test; we 
considered a pathway to be enriched with 
differentially expressed genes if the associated p-value 
was <0.01 [23]. 
Pathway cross-talk quantification 
Interactions between enriched pathways were 
evaluated through a discriminating score (DS) [24]. 
This score was calculated considering the mean and 
standard deviation of the gene expression levels for 
each couple of pathways. Mx and My represent the 
mean of gene expression levels for the pathway x and 
y; SDx and SDy are the standard deviation for the 
pathway x and y. 
DS = |Mx−My|
SDx+SDy
 
Machine learning approach: pathway cross-talk 
network 
We implemented a machine learning model 
using a Random Forest classification of the R-package 
[25](k-cross validation, k=10) in order to select the 
pairwise pathways that achieved the best 
performance in the classification of HER2+ BC and 
NS. The performances were valuated using the Area 
Under Curve (AUC). The classification was repeated 
50 times for each different training dataset, selecting 
the top 10 pairs of pathways for each bootstrap. 
Finally, we selected the pathways that achieved the 
top 10 positions in a major number of boots. The AUC 
performances were validated also using the testing 
dataset.  
miRNAs regulating pathway cross-talk 
network 
Differential expression analysis of miRNAs 
between HER2+ BC and NS was performed using 
TCGAbiolinks package (|logFC| >1 and adjusted 
p-value <0.01) [21]. 
Mutual information was applied between 
differentially expressed miRNAs in HER2+ BC vs NS 
and 15243 genes of the original mRNA dataset, using 
the R-package parmigene [26]. 
Since we obtained a list of genes potentially 
regulated by miRNAs, we evaluated the pathways 
enriched with target genes for each miRNA. In 
particular, using Fisher's exact test, we selected 
miRNAs that are able to regulate the network of 
pathways (p-values<0.01). Furthermore, we selected 
the miRNAs with the highest value of degree centrality 
in the network, namely those able to regulate the 
major number of genes in the pathways [27]. 
We generated a pathway cross talk network, 
considering only the pathways in the top 10 pairs of 
pathways that present at least 2 or more interactions 
with the other pathways and miRNAs. 
BC human tissue samples for ex vivo studies 
We used ten samples of HER2+ BC human tissue 
and corresponding non-tumoral clear margins from 
surgical resections performed from 2011 to 2013 at the 
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Breast Unit of Istituti Clinici Scientifici Maugeri 
IRCCS, Pavia, Italy. Samples referred to the biological 
collection of the “Bruno Boerci” Oncological Biobank 
for research applications (Istituti Clinici Scientifici 
Maugeri IRCCS, Pavia), a biobank certified to ISO 
9001:2015 and member of BBMRI.it (the italian node 
of the BBMRI-ERIC, Biobanking and BioMolecular 
resources Research Infrastructure – European 
Research Infrastructure Consortium). Upon informed 
consent from patients, samples were collected, 
processed and stored at -80°C as snap-frozen 
aliquotes immediately after surgery, according to the 
best practices in biobanking (certification ISO 
9001:2015). At the time of collection, HER2 enrichment 
was assessed through IHC molecular characterization 
by the Pathology Service (Istituti Clinici Scientifici 
Maugeri IRCCS, Pavia), according to the clinical 
guidelines on BC (ASCO – American Society of 
Clinical Oncology). Molecular characterization of the 
tumor samples is shown in Table S1. The samples 
were used for the isolation of total RNA and miRNA 
analysis in real-time PCR (as described in the methods 
below). 
BC cell culture for in vitro studies 
We used SKBR3 cells (ICLC, Genova, Italy), that 
are the reference HER2+, human, BC epithelial cell 
line [28] and MCF10A cells, as human, normal-like 
epithelial breast cells [29]. We maintained the cell line 
within a humidified atmosphere containing 5% CO2 at 
37 °C in DMEM high glucose cell culture medium 
(Gibco, Life Technologies), with 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin, 2mM 
L-Glutamine (Euroclone) following the 
manufacturer’s recommendation. Dulbecco 
Phosphate-Buffered Saline (D-PBS), and trypsin were 
obtained by Lonza (Euroclone). 
RNA extraction and real time-PCR analysis 
Total RNA of both cell lines and human samples 
was isolated using TRIzol reagent (Life Technologies) 
following the manufacturer’s recommendations and 
as already described in [29]. For miRNA 
quantification, total RNA was reverse transcribed 
using MystiCq microRNA cDNA synthesis kit (Sigma 
Aldrich), following manufacturer’s recommendations. 
miRNAs were amplified in Eco real time-PCR 
(RT-PCR) (Illumina, Euroclone) using Power Up Sybr 
green mix (Applied Biosystem) in combination with 
homemade designed primers (Sequences in the Table 
S2). For each RT-PCR analysis the results are 
presented as 2^-∆∆Ct method [30] normalizing the 
results on the expression of a miR-103-3p (Table S2) 
and the positive control of the MystiCq microRNA 
cDNA synthesis kit. 
miRNA modulation 
miRNA increase or decrease were obtained in 
SKBR3 cell line by transfection of sense or antisense 
oligonucleotide (Sigma Aldrich) with metafectene 
reagents (Biontex, Germany), following 
manufacturer’s instruction. The sequences for miRNA 
modulation are in Table S2. All miRNA 
oligonucleotides were designed on the sequences 
from miRbase database [31].  
MTT assay 
SKBR3 cells were seeded in 96 wells at 5000 
cells/well. 48h after seeding the cells were treated 
with Scramble S or As miR-429 oligonucleotide for 
miRNA modulation. At 24, 48 and 72h after treatment, 
the cells were stained with 50ug/ul of thiazolyl blue 
tetrazolium bromide (MTT) (Sigma Aldrich) for 4 h at 
37°C and then lysed in dimethyl sulfoxide (DMSO; 
Euroclone, Italy). The staining was quantified at 
540nm in FLUOstar Omega microplate reader 
(Euroclone). The presented results are the 
average±standard deviation (sd) of three independent 
experiments. 
Wound-healing assay  
The SKBR3 cells were seeded at a confluence of 
100000/well in 24-well plate (Euroclone). After 48 h, 
necessary to reach 80% confluency, a scratch was 
performed in the middle of each well, as described in 
[29]. After washing the cells, new fresh medium was 
added, and miRNAs were modulated by transfection, 
as described before. Pictures of each well were taken 
every 24 h. The effect on cell migration was quantified 
by ImageJ software, following the protocol described 
in [32]. Experiments were performed in triplicate 
(n = 9) and a t test was calculated. 
Cell invasion in Boyden’s chamber 
To study the invasion ability of the cells, we 
performed the Boyden’s chamber test on SKBR3 in the 
presence of miR-429 silencing. Fifty thousand SKBR3 
cells were seeded on the top of the 70ul coating 
Matrigel (BD) and covered with 350ul of complete 
medium except for 2% FBS. The lower chamber was 
filled with complete medium. One hour after seeding, 
the cells were treated with 150nM scramble or As 
miR-429 oligonucleotides. Twenty-four hours later, 
cells migrated through the Boyden’s chamber, were 
fixed in 4% PFA and stained with cresyl violet for 5 
minutes (min.). Ten pictures for each condition were 
taken and the stained cells were count. The 
experiment was performed in triplicate and the 
average of the migrated cells is calculated.  
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HER2+ BC animal model for in vivo treatment 
studies 
Animal experiments were carried out in 
compliance with the institutional guidelines for the 
care and use of experimental animals (European 
Directive 2010/63/UE and the Italian law 26/2014), 
authorized by the Italian Ministry of Health and 
approved by the Animal Use and Care Committee of 
the University of Milan. Ten female nude mice 
(athymic nude-Foxn1 Nu/Nu, Envigo), 7-8 weeks old, 
were all xenografted to model HER2+ BC with 5 
million SKBR3 cells in Matrigel injected in mammary 
gland. During in vivo study, mice were maintained on 
a 12-h light–dark cycle in cages of five animals with 
water and food ad libitum (environment of 23 ± 1°C 
and 50 ± 5% humidity). After detection of the tumors 
(about 20 days), the animals were divided in two 
groups: the first group was treated with 5 pM 
scramble S oligonucleotide in the presence of 
Atelogene as vehicle; the second group was treated 
with 5 pM As miR-429 in the presence on Atelogene as 
vehicle. One animal was treated with vehicle alone. 
Tumor growth was followed over time by 
measurements of the three dimensions of the palpable 
masses (height x length x depth) and the tumor 
volume was calculated by multiplying the three 
dimensions of the tumor measured by caliper. 
For ex vivo studies, at the end of the experiments, 
mice were sacrificed by cervical dislocation after 
sedation, and tumours were explanted 
for immune-histochemical and molecular analyses. 
 Luciferase assay 
To assess if VHL is a direct target of miR-429, 
pGL3-control vector or pGL3-VHL-WT was 
transfected with lipofectamine 3000 (Invitrogen) in 
SKBR3 cells, according to the manufacturer’s 
suggestion, in combination with 100 nM mimic 
miR-429 or miR-142 (a known regulator of VHL) or 
scramble miR sequence. After 24 h, Gaussia 
Luciferase (GLuc) activity was measured in the 
collected medium and normalized on the Secreted 
Alkaline Phosphatase (SEAP) content. Results were 
detected by Glomax (GloMax-Multi Detection System; 
Promega, Madison, WI, USA). 
Western blot analysis 
Western blot on total protein lysates was 
performed as described in [29]. Anti VHL or anti actin 
antibodies (both Santa Cruz Biotechnologies) was 
used 1:500 overnight in 3% skimmed milk and the 
secondary anti-mouse HRP (Santa Cruz 
Biotechnologies) was used 1:1000 1 h at room 
temperature in 3% skimmed milk. Membranes were 
developed using the SuperSignal West Pico 
Chemiluminescent Substrate (ThermoScientific, 
France) on Amersham Hyperfilm MP (Ge Helthcare, 
Italy). The blots of both proteins were quantified by 
ImageJ software (http://imagej.nih.gov/ij/). 
Experiments were performed two times in triplicate. 
Hypoxia induction 
In order to study the effects of hypoxia on 
miR-429 expression, we used a hypoxic chamber [33]. 
During hypoxia experiments, SKBR3 cells were 
seeded at 150000 cells/w in a 6 wells’ plate and 
incubated in the hypoxic chamber containing 1% O2 
gas mixture for 24 h (h). After this treatment, the cells 
were used for RNA extraction and RT-PCR analysis of 
miR-429 expression. 
Results 
Computational approach predicted that 
miR-190, miR-429 and miR-584 have a central 
role in the diagnosis of HER2+ BC 
We found 222 pairwise pathways that obtained 
an AUC value in the top 10 positions in at least one 
bootstrap in discriminating HER2+ BC versus NC. 
Figure 2A shows the distribution of the 222 pairwise 
pathways in the top 10 positions for each boot. Then, 
we selected the 10 pairwise pathways that achieved 
the best performances in all bootstraps (Figure 2B). 
Overall, the selected pairwise pathways obtained an 
AUC value of 0.98 in the training and 0.94 in the 
testing data set (Figure 2C). 
We identified miRNAs regulating the selected 
pairwise pathways generating a diagnostic 
pathway-miRNA network. 
We focused on 3 miRNAs altered in HER2+ BC 
indicating the number of genes potentially regulated 
by each miRNA obtained by mutual information 
approach, on the total number of genes in the coupled 
pathway. In our study we considered those miRNAs 
with the highest degree centrality, miR-190, miR-429 
and miR-584. From our analysis miR-429 control 33 
genes over 484 in 3 coupled pathways, miR-190 and 
miR-584 controls 30 and 49 genes over 693 in 3 and 2 
coupled pathways, respectively (Table S3). We 
selected the pathways and miRNAs with the highest 
degree centrality (HDC) obtaining a network of 7 
pathways and 3 miRNAs (Figure 3).  
miR-429 regulates the major number of 
pathways: "HIF1 signaling", "Acute Phase Response 
signaling", "Glioblastoma Multiforme signaling", "P2Y 
Purigenic Receptor signaling", "CXCR4 signaling " 
and “Growth hormone signaling”. miR-584 regulates 
"P2Y Purigenic Receptor signaling", "CXCR4 
signaling" and "Axonal Guidance signaling". miR-190 
regulates "P2Y Purigenic Receptor signaling", "Axonal 
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Guidance signaling", "CXCR4 signaling" and 
"Glioblastoma Multiforme signaling".  
In vitro studies confirmed that miR-190, 
miR-429 and miR-584 are diagnostic molecules 
for HER2+ BC  
To evaluate if the expression levels of miR-190, 
-429 and -584 are different in HER2+ versus 
normal-like epithelial cells, as predicted by in silico 
analysis, we performed RT-PCR assay of these three 
miRNAs in both cell line and human BC samples. The 
SKBR3 HER2+ cells compared to MCF10A cells have 
significantly higher levels of miR-429 compared to 
normal-like cells (Figure S1A and Figure S2) and 
lower levels of both miR-190, and miR-584 (Figure S1B 
and C, respectively).  
ex vivo studies confirmed that miR-190, miR-429 
and miR-584 are diagnostic molecules for 
HER2+ BC 
In order to understand if the three miRNAs 
could be proposed as diagnostic molecules for HER2+ 
BC, we analysed the level of expression of miR-190, 
miR-429 and miR-584 in human BC HER2+ samples 
compared to normal surrounding epithelial 
mammary tissue. The RT-PCR experiment revealed 
that all the miRNAs are differentially expressed, 
being miR-429 significantly upregulated and miR-190 
and miR-584 significantly downregulated in human 
HER2+ BC samples (Figure 4A-C). In particular, 
considering the expression level of each miRNA in 
healthy tissue, miR-190 and miR-584 are 
downregulated to 0.84±0.57 and 0.49±0.40 
respectively, while miR-429 is upregulated to 
11.23±12.95.  
In vitro downregulation of miR-429 blocked the 
proliferation and decreased migration and 
invasion of HER2+ BC cells 
As miR-429 role in HER2+ BC is unknown and as 
it is the only miRNA upregulated in HER2+ BC, we 
analysed the effect of miR-429 silencing in HER2+ BC 
cell line. No correlation was observed between the 
different stages of BC and the miR-429 expression 
level (Figure S3). Several of the target genes of 
miR-429 are involved in the control of proliferation 
(i.e. ‘HIF1 signaling’). We thus analyzed the effect of 
miRNA reduction on proliferation, by MTT assay. The 
significant downregulation of miR-429, obtained by 
200nM As oligonucleotide treatment in SKBR3 cells 
for 72 h (Figure S4A), caused a delay in the 
proliferation rate (Figure 5A), that was statistically 
significant compared to scramble-treated cells (t test p 
value <0.05 *, <0.01 **). Similar results were obtained 
on another HER2+ BC cell line (MDA-MB-453, data in 
Figure S4C). 
 
 
Figure 2. Computational approach results Frequency of pairwise pathways in the top 10 for all 50 bootstraps (A). Pathways achieving the best performance in all 50 
bootstraps (B) Boxplot representation of the AUC values in the training and testing dataset (C). 
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Figure 3. Pathway cross-talk networks in HER2 BC and their regulatory miRNAs. In red are indicated miRNAs and their connections, in blue are the functional 
pathways and their connections with the corresponding p-values.  
 
Figure 4 miR-429 is overexpressed, while miR-190 and miR-584 are downregulated in HER2+ human BC. RT-PCR analysis of the fold change expression levels of 
miR-190 (A), miR-429 (B) and miR-584 (C) in HER2+ BC human samples compared to their corresponding healthy mammary tissue. The smaller panels in plot 4A and 4C 
represent an enlargement of the starting plot. The average value is indicated in red (n=10 samples, T test, p value<0.05, *).  
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Figure 5. miR-429 controls HER2+ BC cell proliferation , migration and invasion. MTT assay was performed on SKBR-3 cell at 0, 24, 48 h after 200nM Scramble or As 
miR-429 oligonucleotide treatment. The results are the average of three independent experiments in triplicate (t test compared to scramble treated cells, p value <0.05, *; <0.01, 
**)(A). 200nM 72h treatment with As miR-429 reduced the expression of CDK4 significantly (t test n=2 experiments in triplicate, p value <0.01**)(B). Wound healing test was 
performed on SKBR-3 treated with 200nM scramble oligonucleotide or As miR-429 in culture for 9 days. In each sample, the wound area was quantified by Image J following [31](t 
test compared to scramble-treated cells; n=3 experiments in triplicate, p value <0.01, **) (C). Boyden’s chamber test was performed on SKBR-3 in the presence of 150nM 
scramble or As miR-429 in culture for 24h. The count of the cells was performed on 10 images from each sample (t test compared to scramble-treated cells; n=3 experiments, 
p value<0.01, **) (D).  
 
The observed reduction of proliferation rate 
observed in SKBR3 cells treated with As miR-429 
could be due to a reduction of CDK4 expression, thus 
possibly causing a block in G1 to S phase transition 
(Figure 5B).  
Considering that miR-429 is predicted by in silico 
analysis to regulate also pathways involved in cell 
migration and invasion (i.e CXCR4 pathway), we 
focused on the effects of As miR-429 modulation in 
wound healing and Boyden’s chamber tests. In the 
first assay, we quantify the area of the wound at each 
time point in SKBR3 cells treated with Scramble S or 
As miR-429 oligonucleotides and normalized on that 
of the 24h (as suggested in [32]) (Figure S4B), 
calculating the percentage of wound closure at each 
time point. The delay of the As miR-429 treated SKBR3 
cells in wound closure was significantly different 
from the scramble-treated cells (Figure 5C). 
In the second assay, we observed that the 
treatment of 150nM As miR-429 reduced significantly 
the migration ability of HER2+ SKBR3 cells compared 
to the scramble-treated cells (Figure 5D).  
In vivo downregulation of miR-429 blocked 
tumor proliferation 
To propose miR-429 as a target for therapeutic 
tool development for HER2+ BC, we tested the 
efficacy of As miR-429 treatment on the in vivo growth 
of HER2+ BC tumors. In particular, we treated the 
tumors formed by 5 million SKBR3 xenografted in ten 
NOD/SCID mouse mammary glands with different 
condition (Figure S5A). The animals treated with 
atelogene vehicle (n=1), or scramble oligonucleotide 
and atelogene (n=4) developed rapidly growing 
tumors. In those treated with As miR-429 and 
atelogene (n=5) the growth of the tumor was delayed, 
with a significant difference at day 13 and 15 after 
therapeutic treatment, measured by tumor volume 
(Figure 6A), and by tumor weight at day 15 (Figure 
6B), when the tumors were explanted and the mice 
were sacrificed. Representative pictures of treated 
tumors are presented in Figure S5B. In these tumors, 
we observed that the reduction of miR-429, obtained 
by As treatment, induced VHL increase and a parallel 
decrease of HIF1α targets, such as SLUG, VEGF and 
SNAIL (Figure S7). 
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Figure 6. As miR-429 counteracts the growth of HER2+ BC tumors xenografted in mouse. Tumors formed by SKBR3 in NOD/SCID mouse were treated with As 
miR-429 or scramble S oligonucleotide in the presence of atelogene reagent (vehicle). The volume of each tumor (height x length x depth) was measured at different time points 
and the curves represent the average volume in 15 days of measurements (A). The weights of the five Scramble S- or As miR-429-treated tumors are represented (t test p 
value<0.01, **, n=5) (B).  
 
 
Figure 7. VHL is the direct target of miR-429. Luciferase assay: HER2+ cells were transfected with the Luciferase+ 3’UTR VHL (pGL3-VHL) construct alone, with 100nM 
48h S Scramble or S miR-142 or As miR-429. The luciferase expression (LUC) was normalized on alkaline phosphatase content (AP). The chart represents the percentage of 
LUC/AP ratio (T test, p value<0.05, *; n=2 independent experiment)(A). RT-PCR analysis revealed that miR-429 modulation, obtained with 50nM As miR-429 for 72h (B), caused 
a significant increase of VHL expression, both at mRNA (C) and protein levels (D) (T test, p value<0.05, *; n=3 independent experiment). RT-PCR analysis on human HER2+ BC 
samples revealed that miR-429 is downregulated, compared to healthy tissue (E).  
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Figure 8. miR-429 is induced by hypoxia. RT-PCR analysis on SKBR3 revealed that 24h of hypoxia is able to induce miR-429 increased expression (A). The hypoxia induction 
has been verified by the RT-PCR analysis of HIF1α and its target VEGF mRNA induction (B). 
 
VHL signaling pathway is target of miR-429 
As VHL is predicted to be a putative miR-429 
direct target (TargetScan and miRbase bioinformatics 
tools), we analyzed in detail the 3’ untranslated 
regions (3’UTR) of human VHL target mRNA, and we 
found a possible seed for miR-429 (Figure S6). Thus, 
the dual luciferase reporter assay was performed to 
test if miR-429 is able to directly interact with 3’UTR of 
VHL. When we overexpressed the luciferase-3’UTR 
VHL construct in the presence of As miR-429, we 
observed a significant increase in luciferase activity 
compared to that observed in the cells co-trasfected 
with the same construct and the scramble 
oligonucleotide (Figure 7A). As a control, we 
performed the same transfection using the S miR-142, 
a known regulator of 3’UTR of human VHL [34]. 
Moreover, the in vitro downregulation of 
miR-429 in HER2+ SKBR3 (Figure 7B) cells also caused 
a parallel upregulation of VHL mRNA and protein 
expression (Figure 7C and D, respectively). 
To confirm the possible relation among miR-429 
and VHL target, we performed RT-PCR analysis of 
VHL expression on the human BC samples: as 
expected, VHL is downregulated in human HER2+ 
BC samples, compared to healthy surrounding tissue 
(Figure 7E). 
miR-429 is induced by hypoxia. 
Being VHL a key component of hypoxia 
pathway, we analyzed the effect of hypoxia induction 
on miR-429 expression levels (Figure 8). The RT-PCR 
analysis of miR-429 expression in SKR3 after 24h of 
hypoxia treatment revealed that this condition is able 
to statistically increase miR-429 expression (Figure 
8A). The efficacy of hypoxia induction was evaluated 
by analyzing HIF1α and its target VEGF mRNA 
expression, which are upregulated after hypoxia 
treatment (Figure 8B and C). 
Discussion 
Different miRNA signatures have been already 
proposed to have diagnostic or prognostic properties 
(i.e.[35, 36]). In this paper, we evaluated the diagnostic 
potential of three miRNAs, miR-190, miR-429 and 
miR-584, and the theranostic role of miR-429 in HER2+ 
BC. Although these miRNAs could be de-regulated in 
other BC subtypes, only in HER2+ they are altered 
being regulators of a specific pathway cross-talk 
network. Indeed, these miRNAs have been selected 
with an integrative bioinformatics approach relying 
on those miRNAs with a higher degree centrality in 
controlling a group of functional pathways containing 
differentially expressed genes, altered in HER2+ BC 
versus normal mammary tissues. RT-PCR analysis 
confirmed that miR-429, as well as miR-190 and 
miR-584, are differentially expressed in both HER2+ 
BC cell lines, and in human HER2+ BC tissues 
(miR-190 and miR-584 downregulated and miR-429 
upregulated). Although miR-584 and miR-190 are 
already known tumor suppressor (i.e. [37, 38]), our 
results suggested a possible use of all these 3 miRNAs 
for diagnostic purpose. 
We selected miR-429 as a possible therapeutic 
molecule, being the only upregulated miRNA among 
the three, and having a high degree centrality in 
controlling differentially expressed genes involved in 
"HIF1 signaling", "Acute Phase Response signaling", 
"Glioblastoma Multiforme signaling", "P2Y Purigenic 
Receptor signaling", "CXCR4 signaling " and “Growth 
hormone signaling”. In other tumors, as colorectal 
cancer, non-small cell lung cancer and triple negative 
BC, miR-429 has been proposed as a regulator of 
metastatic properties of the cells [39, 40]. Our in vitro 
experiments on HER+ cells suggested that miR-429 
has a role in controlling cell proliferation (MTT assay), 
possibly via Cyclin-dependent kinase 4 (CDK4) as in 
colorectal cancer [41], and confirmed also that 
miR-429 is involved in migration and invasion 
(wound healing and Boyden’s chamber tests, 
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respectively). These results, obtained by As miR-429, 
could be due to its direct targeting of VHL gene (dual 
luciferase reporter assay). VHL codifies for a tumor 
suppressor protein involved in the degradation of 
hypoxia-inducible factor alpha (HIF1α) and the 
stromal-derived factor-1 receptor (CXCR4) proteins, 
which leads to the block of angiogenesis and tumor 
cell migration [42]. It is already known that VHL is 
underexpressed in highly aggressive and grade 
2-grade 3 BC tumors, with a specific significant 
reduction of VHL expression in those tumors that 
form recurrence [43]. As VHL is a component of the 
HIF1α pathway, as hypoxia is one of the main 
functions affected in solid tumors (i.e. [44]), and 
having VHL increase an impact on triple negative BC 
cell growth [45], we speculated that the As miR-429 
treatment, increasing mRNA of VHL, impacts on 
HIF1α protein degradation, leading to cell 
proliferation inhibition and to the block of metastatic 
potential of the HER2+ cells. Our in vitro experiments 
proved that As miR-429 caused a delay of HER2+ cell 
growth and block invasion and migration ability of 
the cells. Our in vivo experiments on HER2+ BC 
mouse models confirmed that the silencing of miR-429 
impact on tumor cell growth and on tumor volume. 
These effects on cell proliferation and cell 
migration/invasion are possibly due to the decrease 
of HIF1α target mRNAs, such as SNAIL, VEGF and 
SLUG, (as shown in Figure S5) suggesting the use of 
As miR-429 as a new therapeutic option for HER2+ BC 
patients. Moreover, we showed that the hypoxia 
treatment, which is a common state for several HER2+ 
BC tumors, induces miR-429 expression; indeed, it has 
been demonstrated that overexpression of HER2 is 
able to induce HIF1 pathway components [46]. 
Further research is needed to understand the in vivo 
effects of As miR-429 on metastatic potential of 
HER2+ BC tumors. However, the use of As miR-429 
could be considered as a novel tool to be combined 
with classical chemotherapeutic drugs, such as 
trastuzumab, for HER2+ BC treatment. Some 
limitations of the use of miRNA-based therapy need 
to be overcome, in particular those regarding the 
systemic toxicity and the tissue targeting of the 
miRNA [47]. Nevertheless, the combination of two 
drugs, one miRNA-based and one chemotherapeutic 
agent, could increase benefits to the patient by 
reducing the dose of chemotherapy and thus lowering 
its systemic toxicity. 
In order to reduce the miRNA-mediated 
off-target effects and to better address the 
miRNA-based therapy to HER2+ BC tissues, we could 
take adantage of new emerging approach, i.e. those 
that use lipo-complexes conjugated with tumor 
targeting molecules, cationic polymers, conjugation of 
miRNA with lipids or receptor-binding molecules to 
increase cellular uptake, limiting the spreading of the 
drug in other organs [48]. 
In conclusion, from our results we proposed 
miR-190, miR-429 and miR-584 as diagnostic molecules 
for HER2+ BC, being miR-190 and miR-584 
downregulated and miR-429 upregulated in HER2+ 
BC. The miR-429 increase could be induced by 
hypoxia, a common phenomenon for HER2+ BC. The 
silencing of miR-429, by regulating cell proliferation 
and invasion by targeting VHL mRNA, could be 
proposed a new anti-proliferative and anti-metastatic 
therapeutic strategy, alone or in combination with 
other drugs, for HER2+ BC patients’ treatment. 
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